Known targets — ChEMBL curated mechanism
BRAFFLT1FLT3FLT4KDRKITPDGFRBRAF1RET
The experimentally established mechanism targets of Sorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.98 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 0.98 |
| ▸ | RET known ✓ | P07949 | 4/20 | 0.98 |
| ▸ | BRAF known ✓ | P15056 | 4/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.98 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.98 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.98 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.98 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.98 |
| ▸ | ABL1 | P00519 | 3/20 | 0.98 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.98 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.98 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.98 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
| ▸ | HTR1A | P08908 | 2/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.98 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorafenib SCHEMBL1702117 | 0.99 | RAF1 (0.96) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL1701746 | 0.99 | RAF1 (0.96) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL29349634 | 0.99 | RAF1 (1.00) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL8218 | 0.99 | RAF1 (1.00) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL14739751 | 0.99 | RAF1 (1.00) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL1533982 | 0.98 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL1896610 | 0.98 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL18863920 | 0.98 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL28817561 | 0.98 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 | |
| Sorafenib SCHEMBL28894639 | 0.98 | RAF1 (0.98) | RAF1KDRRETBRAFEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604208-B2 | Polymorphs of sorafenib acid addition salts | RANBAXY LABORATORIES LIMITED (IN) | 2013-12-10 | — | — | US | claimed |
| US-20120264789-A1 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS | RANBAXY LABORATORIES LIMITED (IN) | 2012-10-18 | — | — | US | claimed |
| EP-2480535-A1 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS | Ranbaxy Laboratories Limited (IN) | 2012-08-01 | — | — | EP | claimed |
| EP-2440531-A2 | POLYMORPHS OF 4-[4-[[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYLAMINO]PHENOXY]-N-METHYL-PYRIDINE-2-CARBOXAMIDE | Ratiopharm GmbH (DE) | 2012-04-18 | — | — | EP | claimed |
| WO-2011036648-A1 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-31 | — | — | WO | claimed |
| WO-2010142678-A2 | POLYMORPHS OF 4-[4-[[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYLAMINO]PHENOXY]-N-METHYL-PYRIDINE-2-CARBOXAMIDE | RATIOPHARM GMBH (DE) | 2010-12-16 | — | — | WO | claimed |
| CN-117088809-A | Sorafenib-malonic acid eutectic crystal and preparation method thereof | 浙江工业大学 | 2023-11-21 | — | — | CN | disclosed |
| US-20230159644-A1 | FLT3-TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS FOR TREATMENT OF FLT3-POSITIVE MALIGNANCIES | HOPE CITY (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4135851-A1 | FLT3-TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS FOR TREATMENT OF FLT3-POSITIVE MALIGNANCIES | City of Hope (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-115397517-A | FLT 3-Targeted chimeric antigen receptor-modified cells for the treatment of FLT 3-positive malignancies | 希望之城 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021212069-A1 | FLT3-TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS FOR TREATMENT OF FLT3-POSITIVE MALIGNANCIES | CITY OF HOPE (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20210301024-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY TARGETING FLT3, PD-1, AND/OR PD-L1 | CYTOIMMUNE THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| CN-113383071-A | Compositions and methods for T cell engineering | 亘喜生物科技（上海）有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-8604208-B2 | Polymorphs of sorafenib acid addition salts | RANBAXY LABORATORIES LIMITED (IN) | 2013-12-10 | — | — | US | disclosed |
| US-20130274478-A1 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS | RANBAXY LABORATORIES LIMITED (IN) | 2013-10-17 | — | — | US | disclosed |
| US-20120264789-A1 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS | RANBAXY LABORATORIES LIMITED (IN) | 2012-10-18 | — | — | US | disclosed |
| EP-2480535-A1 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS | Ranbaxy Laboratories Limited (IN) | 2012-08-01 | — | — | EP | disclosed |
| EP-2440531-A2 | POLYMORPHS OF 4-[4-[[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYLAMINO]PHENOXY]-N-METHYL-PYRIDINE-2-CARBOXAMIDE | Ratiopharm GmbH (DE) | 2012-04-18 | — | — | EP | disclosed |
| WO-2011036648-A1 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-31 | — | — | WO | disclosed |
| WO-2010142678-A2 | POLYMORPHS OF 4-[4-[[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYLAMINO]PHENOXY]-N-METHYL-PYRIDINE-2-CARBOXAMIDE | RATIOPHARM GMBH (DE) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264789-A1 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS | TP53, HCCS, SF3B5 | RAF1 133/4885KDR 152/4885RET 343/4885 |
| US-20130274478-A1 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS | TP53, HCCS, SLC10A1 | RAF1 131/4885KDR 118/4885RET 331/4885 |
| US-20210301024-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY TARGETING FLT3, PD-1, AND/OR PD-L1 | FLT3, CD274, PDCD1LG2 | RAF1 385/4885KDR 371/4885RET 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.